36 Years of Excellence in Sulfonamides: Wugan Pharmaceutical Leads the Global Niche Market

In the Tongguan Industrial Park of Wangcheng Economic and Technological Development Zone, Changsha, a global "champion" enterprise in the sulfonamide API sector—Hunan Wugan Pharmaceutical Co., Ltd.—is reshaping the global pharmaceutical excipient landscape through outstanding R&D capabilities and intelligent manufacturing. Founded in 1987, Wugan Pharmaceutical has dedicated 36 years to the production of sulfonamide series products. Currently, the company operates two manufacturing facilities, located in Suzhou and Changsha.

Company Profile: Deep Industry Roots, Strategic Relocation to Hunan

Established in 2017, Hunan Wugan Pharmaceutical Co., Ltd. is a national high-tech enterprise specializing in the R&D, production, and sales of pharmaceutical APIs, veterinary drugs, and food additives. With a total investment of 2.2 billion RMB and covering an area of over 200 mu (approximately 13.3 hectares), the company operates as a green, energy-saving biomedical manufacturing base integrating scientific research, production, and business operations. In 2020, the company strategically relocated its group headquarters from Suzhou, Jiangsu, to Changsha, becoming the first pharmaceutical enterprise to move its entire headquarters from another province to Wangcheng. This move underscores its strategic commitment to establishing a strong presence in Central China while expanding its global reach.

Flagship Products: Focused on Sulfonamides with a Comprehensive Portfolio

The company's core products are centered on sulfonamide APIs, boasting the world's most complete product variety, largest production scale, and longest product chain within this category. Its main products include dozens of varieties such as Sulfadiazine, Sulfamethoxazole, Crystalline Sulfanilamide, Sulfaguanidine, Sulfadimidine, and Sulfaquinoxaline. Furthermore, the company's business extends to biological buffers, intermediates for anti-diabetic drugs, and new energy functional materials.

Industry Strengths: Technological Leadership and Global Presence

• Market Dominance: The company holds a dominant position in the global sulfonamide API market, consistently maintaining a market share of over 40%, with figures for some products exceeding 50%.

• International Quality Systems: Its products have successfully passed on-site FDA inspections and hold European COS (Certificate of Suitability) certifications, and have also received China Veterinary Drug GMP approval, ensuring its quality systems align with rigorous international standards.

• Intelligent and Green Manufacturing: The company extensively utilizes industry-leading intelligent production lines, boosting production efficiency by over 50%. It is equipped with world-class wastewater treatment systems, underscoring its commitment to building a green factory.

• R&D and Policy Advantages: Recognized as a "Specialized and Sophisticated" Little Giant enterprise and a Manufacturing Single Champion in Hunan Province, the company has been granted 42 patents. Leveraging Changsha's talent pool and advantageous geographic location, it benefits from an integrated transportation network of rail, road, and waterway, serving markets in over 70 countries and regions worldwide.

Future Vision

Looking ahead, Hunan Wugan Pharmaceutical Co., Ltd. will continue to deepen its expertise in the specialty API sector, striving to build a world-class green biomedical base that integrates R&D, manufacturing, and sales, thereby contributing China's strength to the global cause of life and health.

Enterprise Contact Information

Address: No. 333, Xinyuan Road, Tongguan Circular Economy Industrial Park, Wangcheng Economic and Technological Development Zone, Changsha, Hunan, China

ChemNet Shop: www.chemnet.com/ChinaSuppliers/13997/

Tel: +86-731-81818999;+86-18900791366

Email: alyssa.lu@wugan.com